VIDA
Leader in quantitative lung analysis for COPD, emphysema and asthma, establishing objective, reproducible and quantitative.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $13.0m | Series C | |
| Total Funding | 000k | ||
Related Content
VIDA is a precision lung health company that leverages artificial intelligence to accelerate respiratory clinical trials and improve patient outcomes. The company serves healthcare organizations and physicians by providing advanced imaging solutions and data-driven insights to streamline care coordination and drive efficiencies. Operating in the healthcare and medical research market, VIDA's business model focuses on offering AI-powered tools that enhance the accuracy and efficiency of clinical trials for respiratory diseases such as COVID-19, asthma, COPD, ILD, and lung cancer. VIDA generates revenue through the sale of its VIDA Insights and VIDA Discovery solutions, which hold regulatory clearances in the US and Canada. By modernizing lung and respiratory care, VIDA aims to reduce the high costs and inefficiencies associated with respiratory clinical trials, ultimately accelerating the delivery of new therapies to patients.
Keywords: precision lung health, AI-powered, respiratory clinical trials, healthcare organizations, patient outcomes, imaging solutions, data-driven insights, care coordination, regulatory clearances, respiratory diseases.